Manchester Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Manchester Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,239	Closed	-$16K	–	1023
2021 Q3	$16K	Hold	3,239	–	–	﹤0.01%	542
2021 Q2	$21K	Hold	3,239	–	–	﹤0.01%	438
2021 Q1	$25K	Hold	3,239	–	–	﹤0.01%	424
2020 Q4	$21K	Hold	3,239	–	–	﹤0.01%	424
2020 Q3	$22K	Hold	3,239	–	–	﹤0.01%	380
2020 Q2	$27K	Hold	3,239	–	–	﹤0.01%	411
2020 Q1	$25K	Hold	3,239	–	–	﹤0.01%	411
2019 Q4	$27K	Hold	3,239	–	–	﹤0.01%	416
2019 Q3	$24K	Hold	3,239	–	–	﹤0.01%	419
2019 Q2	$36K	Hold	3,239	–	–	﹤0.01%	407
2019 Q1	$35K	Hold	3,239	–	–	﹤0.01%	452
2018 Q4	$74K	Hold	3,239	–	–	0.01%	317
2018 Q3	$60K	Hold	3,239	–	–	0.01%	342
2018 Q2	$74K	Hold	3,239	–	–	0.01%	324
2018 Q1	$92K	Hold	3,239	–	–	0.01%	292
2017 Q4	$68K	Hold	3,239	–	–	0.01%	317
2017 Q3	$59K	Hold	3,239	–	–	0.01%	321
2017 Q2	$50K	Hold	3,239	–	–	0.01%	348
2017 Q1	$56K	Hold	3,239	–	–	0.01%	339
2016 Q4	$36K	Hold	3,239	–	–	0.01%	378
2016 Q3	$51K	Hold	3,239	–	–	0.01%	356
2016 Q2	$33K	Buy	+3,239	New	+$36.9K	﹤0.01%	404

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Manchester Capital Management's CTMX Position: Q4 2021 in Review

Manchester Capital Management sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 3,239 shares — an estimated $16K sold.

Manchester Capital Management first reported a position in CTMX in Q2 2016 and held it in 22 quarters. The position peaked at $92K in Q1 2018. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

Manchester Capital Management reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
Manchester Capital Management sold 3,239 CytomX Therapeutics shares in Q4 2021, an estimated $16K.
Manchester Capital Management first reported a position in CytomX Therapeutics in Q2 2016 and held it in 22 quarters.
Manchester Capital Management's CytomX Therapeutics position peaked at $92K in Q1 2018.
110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Manchester Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.